Physician profile
Ari Chodos
NPI 1114162534
$19,304.34
in general payments reported to CMS, 2019-2025
39 companies · $4,211 in 2025
The $4,211 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,973 · 2020: $659 · 2021: $1,163 · 2022: $1,338 · 2023: $1,545 · 2024: $8,416 · 2025: $4,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,600 · Food and Beverage: $5,029 · Long Term Medical Supply Or Device Loan: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,600.00 |
| Food and Beverage | $5,029.39 |
| Long Term Medical Supply Or Device Loan | $542.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $9,390.69 | 2023-2025 | Voquezna |
| Janssen Biotech, INC. | $1,859.88 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,828.02 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $955.99 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $905.82 | 2019-2024 | Spyglass, Agile Esophageal, Jagtome Rx 39 |
| Pentax of America, INC. | $818.68 | 2020-2025 | Video Colonoscope, Pentax Medical, C2 Cryoballoon |
| Pfizer INC. | $454.00 | 2019-2025 | |
| Celgene Corporation | $399.48 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.93 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $191.47 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $171.15 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $139.15 | 2023-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $136.49 | 2019-2024 | Linzess |
| Ardelyx, INC. | $135.54 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $126.51 | 2023-2024 | Rebyota |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $124.60 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $123.98 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $119.22 | 2024 | |
| Nestle Healthcare Nutrition INC. | $119.10 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $114.93 | 2019 | |
| Ucb, INC. | $110.01 | 2019-2020 | |
| Qol Medical, LLC | $107.85 | 2019-2022 | |
| Braintree Laboratories, INC. | $85.02 | 2019-2024 | Sutab, Suflave |
| Novo Nordisk INC | $85.00 | 2025 | Wegovy |
| Lilly USA, LLC | $72.61 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $65.57 | 2025 | Iqirvo |
| Amgen INC. | $42.25 | 2022 | |
| Celltrion USA INC. | $38.04 | 2024-2025 | Vegzelma, Zymfentra |
| Covidien LP | $32.04 | 2019 | |
| Cook Medical LLC | $30.83 | 2020-2021 | |
| Daiichi Sankyo INC. | $24.76 | 2023 | Injectafer |
| Allergan, INC. | $24.71 | 2019-2020 | |
| Madrigal Pharmaceuticals | $22.94 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $21.46 | 2023 | Fujifilm |
| Organon LLC | $19.54 | 2023 | Renflexis |
| Redhill Biopharma INC. | $17.33 | 2021 | |
| Capsovision, INC. | $16.92 | 2024 | Capsocam Plus |
| Concordia Pharmaceuticals INC. | $14.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Chodos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.